Icon

OXLUMO (nda214103)- (EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML))

LUMASIRAN SODIUM ALNYLAM PHARMS INC
EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML)
No No
2038-Nov-20 2025-Nov-23
None None
None No
OXLUMO is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.